Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...

“This scheme targets patients aged 18 or above who have been diagnosed with asthma, bronchiectasis or chronic obstructive pulmonary disease, and experience persistent respiratory symptoms ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

It is estimated that some 300,000 people in the UK have bronchiectasis, a devastating chronic lung condition that causes excess mucus to build up in the lungs, resulting in frequent coughing and ...

ICS users had a more severe bronchiectasis phenotype with increased radiologic severity, an elevated daily sputum volume, and increased use of other therapies. Inhaled corticosteroids (ICS) use is ...

This causes thick mucus production in the airways, leading to chronic infections and bronchiectasis with resulting marked decline in pulmonary function. The only treatment for end-stage CF lung ...

Researchers have discovered in a new study that treating airway inflammation with the experimental drug brensocatib lowers the rate of pulmonary exacerbations in patients with bronchiectasis. The ...

Objective To accurately estimate the global prevalence of non-tuberculous mycobacteria (NTM) in adults with non-cystic fibrosis (non-CF) bronchiectasis and to determine the proportion of NTM species ...

Some of the bronchiectasis and bronchiolectasis resolved. In two patients bronchiectasis and bronchiolectasis occurred at one year and two years of follow up, respectively. In two patients with ...

Visit a quote page and your recently viewed tickers will be displayed here.